Balar AV et al. Pembrolizumab (pembro) in combination with gemcitabine (gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial. ASCO 2021;Abstract 4504.
Bellmunt J et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): A multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2021;22(4):525-37. Abstract
Do MH et al. Dermatologic infections in cancer patients treated with checkpoint inhibitors. J Am Acad Dermatol 2021;S0190-9622(21)00586-7. Abstract
Francis JH et al. Clinical and morphologic characteristics of fibroblast growth factor receptor inhibitor-associated retinopathy. JAMA Ophthalmol 2021;e213331. Abstract
Funt SA et al. Neoadjuvant atezolizumab (A) with gemcitabine and cisplatin (GC) in patients (pts) with muscle-invasive bladder cancer (MIBC): A multicenter, single-arm, phase 2 trial. ASCO 2021;Abstract 4517.
Guercio BJ et al. Developing precision medicine for bladder cancer. Hematol Oncol Clin North Am 2021;35(3):633-53. Abstract
Heath EI, Rosenberg JE. The biology and rationale of targeting nectin-4 in urothelial carcinoma. Nat Rev Urol 2021;18(2):93-103. Abstract
Hussain MHA et al. IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC). ASCO 2020;Abstract 5000.
Lyou Y et al. Relationship between hyperphosphatemia with infigratinib (BGJ398) and efficacy in FGFR3-altered advanced/metastatic urothelial carcinoma (aUC). ASCO Genitourinary Cancers Symposium 2021;Abstract 576.
Powles T et al. Beyond chemotherapy and checkpoint inhibitors: Weighing the risks and benefits of the novel therapies for metastatic urothelial carcinoma. J Clin Oncol 2021;JCO2101430. Abstract
Powles T et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 2021;384(12):1125-35. Abstract
Rosenberg JE et al. Analysis of hard-to-treat subgroups from EV-301: A phase III trial of enfortumab vedotin (EV) vs chemotherapy for previously treated advanced urothelial carcinoma. ESMO 2021;Abstract 698P.
Sarfaty M et al. Detection of FGFR3 alt in plasma cfDNA in metastatic UC patients receiving Erda therapy. ASCO 2021;Abstract e16519.
Teo MY et al. Clinicogenomic predictors of extreme responses to anti-PD1/PDL1 checkpoint inhibitors (CPI) in metastatic urothelial cancer (mUC). ASCO 2020;Abstract 5050.
Wong JL, Rosenberg JE. Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma. Expert Opin Biol Ther 2021;21(7):863-73. Abstract